Get the Stockscreener App
1.65
35.08%
0.41
After Hours:
1.65
Opko Health Inc stock is traded at $1.65, with a volume of 34.40M.
It is up +35.08% in the last 24 hours and up +9.48% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.24
Open:
$1.38
24h Volume:
34.40M
Relative Volume:
10.86
Market Cap:
$1.25B
Revenue:
$581.12M
Net Income/Loss:
$-212.92M
P/E Ratio:
-6.0263
EPS:
-0.2738
Net Cash Flow:
$-174.22M
1W Performance:
+38.43%
1M Performance:
+9.48%
6M Performance:
+30.86%
1Y Performance:
+24.07%
1-Day Range:
$1.37
$1.73
1-Week Range:
$1.165
$1.73
52-Week Range:
$0.9769
$1.73
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, IDXX, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.65 | 936.31M | 581.12M | -212.92M | -174.22M | -0.2738 |
TMO
Thermo Fisher Scientific Inc
|
576.42 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.07 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
569.54 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
IQV
Iqvia Holdings Inc
|
243.35 | 35.59B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
140.57 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | JP Morgan | Neutral |
| Oct-31-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results - Benzinga
OPKO Health (NASDAQ:OPK) Shares Gap Up Following Strong Earnings - MarketBeat
Why Is OPKO Health (NASDAQ:OPK) Stock Drawing Fresh Market Interest Today? - Kalkine Media
OPK Looks 19.0% Overvalued on GF Value™ - GuruFocus
OPKO Health, Inc. 2026 Q2 10-Q Report: Financial Statements, Risk Factors, and Management Discussion - Minichart
OPK Looks 17.9% Overvalued on GF Value™ - GuruFocus
OPKO Health Q2 2026 Results: Key Pipeline Advances, Rayaldee China Expansion, and Improved Financial Performance – Minichart - Minichart
OPKO Health (NASDAQ:OPK) Shares Rise After Q2 Earnings Exceed Forecasts; Nicoya Agreement Lifts After-Hours Gains - TechStock²
Earnings call transcript: OPKO Health posts smaller Q2 loss, shares rise in 2026 - Investing.com Canada
OPK: Q2 2026 delivered higher revenue, improved margins, and raised full-year guidance amid pipeline advances - TradingView
OPKO Health Q2 Earnings Call Highlights - MarketBeat
Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
OPK: Profitability improved and revenue grew in Q2 2026, with guidance raised for the full year - TradingView
OPK Looks 17.0% Overvalued on GF Value™ - GuruFocus
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
OPKO Health Inc reports results for the quarter ended June 30Earnings Summary - TradingView
OPKO Health Q2 EPS beats estimates as sales rise 4.3% to $163.5 million - scanx.trade
OPKO Health (NASDAQ:OPK) Issues Earnings Results - MarketBeat
OPKO HEALTH ($OPK) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
OPKO HEALTH, INC. Q2 2026: Revenue $163.6M, EPS $(0.01) — 10-Q Summary - TradingView
OPKO Health: Q2 Earnings Snapshot - Yahoo Finance
(OPK) OPKO Health, Inc. Expects Q3 Revenue Range $131.0M$142.0M - marketscreener.com
OPKO Health reports Q2 2026 revenue $163.5M, operating loss narrows to $7.0M, net loss $8.4M - TradingView
OPKO Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OPK: Q2 2026 revenue rose and losses narrowed, with clinical and partnership progress highlighted - TradingView
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results - OPKO Health, Inc.
OPKO Begins Phase 1 Trials in B-Cell Lymphoma, COVID Prevention - Stock Titan
OPKO Health Inc (OPK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OPKO Health Inc (OPK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OPK|OPKO Health Inc|Price:1.330| - TradingKey
OPK|OPKO Health Inc|Price:1.220|Chg%:+0.050 - TradingKey
OPKO Health Inc (OPK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OPKO Health Inc (OPK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
OPKO Health, Inc. Revenue Breakdown – DUS:XCY - TradingView
OPKO Health Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
OPKO Health Inc (OPK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Here's Why You Should Retain OPK Stock in Your Portfolio for Now - Zacks Investment Research
OPKO Health to Report Second-Quarter 2026 Financial Results on July 27 and Host Conference Call - Quiver Quantitative
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026 - OPKO Health, Inc.
OPKO Health Sets July 27 Webcast for Results and Guidance - Stock Titan
OPKO Health (OPK) Projected to Announce Earnings on Thursday - MarketBeat
Opko Health sets second-quarter results conference call and webcast - Bitget
OPKO Health stock steadies as investors weigh recent earnings and pipeline progress - Ad-hoc-news.de
OPK4048118 Bond Coupon Profile — Rate & Payments - TradingView
OPKO Health, Inc. (NASDAQ:OPK) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
OPKO Health Q1 2026 Earnings: Narrow Loss Meets Estimates as Company Continues Strategic OverhaulConsensus Miss Rate - dars.gov.et
OPK4020628 Bond Risk Profile - TradingView
OPK4048118 Bond Redemption Profile - TradingView
OPK4020628 Bond Coupon Profile — Rate & Payments - TradingView
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Aug 08 '25 |
Buy |
1.32 |
675,000 |
891,000 |
214,676,448 |
1.44%
2.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):